Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

ClinicalTrials.gov ID: NCT04999020

Public ClinicalTrials.gov record NCT04999020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).

Study identification

NCT ID: NCT04999020
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 38 participants

Conditions and interventions

Conditions

Dermatomyositis

Interventions

Ravulizumab Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 19, 2021 (Actual)
Primary completion: Oct 26, 2023 (Actual)
Completion: May 8, 2024 (Actual)
Last update posted: Jul 9, 2025

2021 – 2024

United States locations

U.S. sites: 20
U.S. states: 17
U.S. cities: 20

Facility	City	State	ZIP	Site status
Research Site	Phoenix	Arizona	85032	—
Research Site	Irvine	California	92617	—
Research Site	Santa Monica	California	90404	—
Research Site	Washington D.C.	District of Columbia	20037	—
Research Site	Tampa	Florida	33612	—
Research Site	Atlanta	Georgia	30322	—
Research Site	Chicago	Illinois	60637	—
Research Site	Fairway	Kansas	66205	—
Research Site	Baltimore	Maryland	21205	—
Research Site	Las Vegas	Nevada	89145	—
Research Site	Manhasset	New York	11030	—
Research Site	New York	New York	10021	—
Research Site	Chapel Hill	North Carolina	27599	—
Research Site	Durham	North Carolina	27710	—
Research Site	Cleveland	Ohio	44195	—
Research Site	Pittsburgh	Pennsylvania	15213	—
Research Site	Charleston	South Carolina	29425	—
Research Site	Memphis	Tennessee	38120	—
Research Site	North Richland Hills	Texas	76180	—
Research Site	Seattle	Washington	98122	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04999020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 9, 2025 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04999020 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →